Trends in all-cause pneumonia and otitis media in children aged

.
Source: Human Vaccines and Immunotherapeutics - Category: Allergy & Immunology Authors: Source Type: research

Related Links:

Abstract Pneumococcal disease is a substantial contributor to illness and death in young children globally. The introduction of 7-valent pneumococcal conjugate vaccine (PCV7) in 2000 had a significant impact in preventing pneumococcal disease in both vaccinated children and unvaccinated individuals (through herd effect). A higher valent PCV13 replaced PCV7 in late 2009. This analysis was undertaken to assess how many cases and deaths have been averted over the last decade since PCV13 introduction. A model estimated the number of infants vaccinated annually with PCV13, as well as the number of cases and deaths of i...
Source: Vaccine - Category: Allergy & Immunology Authors: Tags: Vaccine Source Type: research
Pneumococcal conjugate vaccines (PCVs) have led to substantial declines in vaccine-type pneumococcal disease through direct protection of vaccinated persons as well as indirect protection of unvaccinated persons by reducing nasopharyngeal carriage and transmission.1,2 Despite this success, an estimated 4 million pneumococcal disease cases and 22,000 related deaths occur annually in the United States, with otitis media alone causing 1 •5 million cases in 2013.3 These infections are often treated with antibiotics, leading to growing concerns regarding Streptococcus pneumoniae antimicrobial resistance (AMR).
Source: Journal of Infection - Category: Infectious Diseases Authors: Source Type: research
ConclusionsCanadian PCV programs have provided significant health benefits and resulted in a substantial value for money. Net savings achieved over the reviewed period would have provided funding for $1.76  billion in other health care costs or public health initiatives. These findings highlight the importance of considering the total value of a vaccination program, rather than vaccine acquisition costs only, when assessing the value of immunization programs.
Source: Infectious Diseases and Therapy - Category: Infectious Diseases Source Type: research
Streptococcus pneumoniae is a leading cause of childhood morbidity and mortality worldwide (O ’Brien et al., 2009). In 2000, it was estimated that 14.5 million episodes of serious pneumococcal disease occurred, causing 826 000 deaths in children, with over 61% of deaths occurring in African and Asian countries. Since 2000, protein–polysaccharide conjugate vaccines targeting pneumococcal serotypes have been introduced for use in children. Following its widespread use, the 7-valent pneumococcal conjugate vaccine (PCV7) has substantially reduced the incidence of invasive pneumococcal infection, and hospital admiss...
Source: International Journal of Infectious Diseases - Category: Infectious Diseases Authors: Source Type: research
Blue Water Vaccines Inc., a Norwood startup, has entered into an exclusive worldwide license agreement with St. Jude Children ’s Research Hospital to develop a vaccine for Streptococcus pneumoniae. The bacteria can cause many kinds of diseases, including the lung infection pneumonia. “A major limitation of the currently licensed pneumococcal vaccines is the lack of efficacy against mucosal disease manifestations such as acute otitis media, acute bacterial sinusitis and pneumonia,” Blue Water…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news
Conclusion: According to WHO-recommended thresholds for interpreting cost-effectiveness, introduction of PCV-13 for children under 5 years in the Islamic Republic of Iran would be cost-effective. PMID: 31774134 [PubMed - in process]
Source: Eastern Mediterranean Health Journal - Category: Middle East Health Tags: East Mediterr Health J Source Type: research
Outbreaks of severe pneumococcal disease occur sporadically and can affect large numbers of individuals, although they are less frequent compared to the pre-antibiotic era.1 The responsible pathogen, Streptococcus pneumoniae, is a Gram-positive bacterium that commonly colonises the nasopharyngeal tract, especially in young children. Occasionally, however, it can invade locally to cause mucosal infections including sinusitis, otitis media or pneumonia. Rarely, invasion of the bloodstream can lead to more serious infections, including septicaemia and meningitis.
Source: Journal of Infection - Category: Infectious Diseases Authors: Source Type: research
Outbreaks of severe pneumococcal disease occur sporadically and can affect large numbers of individuals, although they are less frequent compared to the pre-antibiotic era.1 The responsible pathogen, Streptococcus pneumoniae, is a Gram-positive bacterium that commonly colonises the nasopharyngeal tract, especially in young children. Occasionally, however, it can invade locally to cause mucosal infections including sinusitis, otitis media or pneumonia. Rarely, invasion of the bloodstream can lead to more serious infections, including septicaemia and meningitis.
Source: Journal of Infection - Category: Infectious Diseases Authors: Source Type: research
Streptococcus pneumoniae is the leading cause of bacterial infections in children, including meningitis, bacteremia, bacteremic pneumonia, empyema, and mucosal infections such as otitis media and non-bacteremic pneumonia. After the implementation of pneumococcal conjugate vaccines (PCVs), worldwide, the burden of invasive pneumococcal diseases (IPDs) and non-invasive pneumococcal diseases due to vaccine serotypes (VTs) greatly decreased in children.1 However, since 2015, several European countries have reported an increased incidence of IPDs due to non-vaccine serotypes (NVTs), which seemed variable across countries in ter...
Source: The Journal of Pediatrics - Category: Pediatrics Authors: Tags: European Paediatric Association Source Type: research
Conclusions: The PHiD-CV vaccination program in Brazil has resulted in important reductions of pneumococcal disease and substantial cost savings. Instead of switching PCVs, expanding vaccine coverage or investing in other health care interventions would be a more efficient use of resources to improve the health of the population in Brazil.
Source: The Pediatric Infectious Disease Journal - Category: Infectious Diseases Tags: Vaccine Reports Source Type: research
More News: Allergy & Immunology | Children | Colombia Health | Meningitis Vaccine | Otitis | Otitis Media | Pneomococcal Vaccine | Pneumonia | Vaccines